Kim Robert Young
Known title: Chief Medical OfficerCIK: 0001971608
Associated companies
Transaction History
| FDMT | ▲ Buy | Option Exercise | 12,000 | $224K | 2/5/2024 | View on chart |
| FDMT | ▼ Sell | Open Market | 12,000 | $361K | 2/5/2024 | View on chart |
| FDMT | ▲ Buy | Option Exercise | 6,000 | $95K | 2/5/2024 | View on chart |
| FDMT | ▼ Sell | Open Market | 6,000 | $180K | 2/5/2024 | View on chart |
| FDMT | ▲ Buy | Option Exercise | 6,000 | $48K | 2/5/2024 | View on chart |
| FDMT | ▼ Sell | Open Market | 6,000 | $180K | 2/5/2024 | View on chart |
| FDMT | ▼ Sell | Open Market | 552 | $17K | 2/5/2024 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 25, 2026
FDMT listed in Benzinga pre-market movers
4D Molecular Therapeutics was mentioned in a Benzinga report on stocks moving lower in Friday’s pre-market session. The article grouped FDMT with other companies like Scholastic and Zscaler, noting a generally downbeat tone among legacy education and other large-cap names. This indicates the stock was part of a broader market movement rather than reacting to a company-specific announcement.
FDMT listed in Benzinga pre-market movers. 4D Molecular Therapeutics was mentioned in a Benzinga report on stocks moving lower in Friday’s pre-market session. The article grouped FDMT with other companies like Scholastic and Zscaler, noting a generally downbeat tone among legacy education and other large-cap names. This indicates the stock was part of a broader market movement rather than reacting to a company-specific announcement.